Skip to content
A Green Sign – Lifestyle
Author:
Protagonist Therapeutics
Protagonist Therapeutics Reports Granting of Inducement Awards
April 16, 2026
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 30, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 5, 2026
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 5, 2026
←
Previous Page
1
2